Alterity Therapeutics Ltd (ATH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alterity Therapeutics Ltd (ATH) has a cash flow conversion efficiency ratio of -0.196x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-10.62 Million ≈ $-7.51 Million USD) by net assets (AU$54.27 Million ≈ $38.40 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ATH net asset quality score to measure how much of total assets are equity-financed.
Alterity Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Alterity Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ATH total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Alterity Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alterity Therapeutics Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
The E&M Co. Ltd
KQ:089230
|
-0.033x |
|
Crosswood
PA:CROS
|
-0.020x |
|
Nordhealth AS
OL:NORDH
|
-0.008x |
|
Idsud S.A
PA:ALIDS
|
-0.907x |
|
Laramide Resources Ltd.
TO:LAM
|
-0.010x |
|
Riber S.A
PA:ALRIB
|
-0.100x |
|
Caravel Minerals Ltd
AU:CVV
|
-0.375x |
|
Fractyl Health, Inc. Common Stock
NASDAQ:GUTS
|
-2.256x |
Annual Cash Flow Conversion Efficiency for Alterity Therapeutics Ltd (2002–2025)
The table below shows the annual cash flow conversion efficiency of Alterity Therapeutics Ltd from 2002 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Alterity Therapeutics Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$42.40 Million ≈ $30.00 Million |
AU$-11.45 Million ≈ $-8.10 Million |
-0.270x | +70.44% |
| 2024-06-30 | AU$13.80 Million ≈ $9.76 Million |
AU$-12.61 Million ≈ $-8.92 Million |
-0.914x | -4.02% |
| 2023-06-30 | AU$22.81 Million ≈ $16.14 Million |
AU$-20.04 Million ≈ $-14.18 Million |
-0.878x | -152.49% |
| 2022-06-30 | AU$35.47 Million ≈ $25.10 Million |
AU$-12.34 Million ≈ $-8.73 Million |
-0.348x | +38.84% |
| 2021-06-30 | AU$30.47 Million ≈ $21.56 Million |
AU$-17.33 Million ≈ $-12.26 Million |
-0.569x | +36.39% |
| 2020-06-30 | AU$10.55 Million ≈ $7.46 Million |
AU$-9.43 Million ≈ $-6.67 Million |
-0.894x | -6.07% |
| 2019-06-30 | AU$16.55 Million ≈ $11.71 Million |
AU$-13.95 Million ≈ $-9.87 Million |
-0.843x | -117.06% |
| 2018-06-30 | AU$16.08 Million ≈ $11.38 Million |
AU$-6.25 Million ≈ $-4.42 Million |
-0.388x | -56.86% |
| 2017-06-30 | AU$23.69 Million ≈ $16.76 Million |
AU$-5.87 Million ≈ $-4.15 Million |
-0.248x | -4.68% |
| 2016-06-30 | AU$31.37 Million ≈ $22.19 Million |
AU$-7.42 Million ≈ $-5.25 Million |
-0.237x | +14.91% |
| 2015-06-30 | AU$39.11 Million ≈ $27.68 Million |
AU$-10.87 Million ≈ $-7.69 Million |
-0.278x | +24.04% |
| 2014-06-30 | AU$37.69 Million ≈ $26.67 Million |
AU$-13.79 Million ≈ $-9.76 Million |
-0.366x | +35.69% |
| 2013-06-30 | AU$13.97 Million ≈ $9.89 Million |
AU$-7.95 Million ≈ $-5.63 Million |
-0.569x | +53.26% |
| 2012-06-30 | AU$5.62 Million ≈ $3.98 Million |
AU$-6.85 Million ≈ $-4.84 Million |
-1.217x | -85.11% |
| 2011-06-30 | AU$6.93 Million ≈ $4.90 Million |
AU$-4.56 Million ≈ $-3.23 Million |
-0.658x | +26.97% |
| 2010-06-30 | AU$5.23 Million ≈ $3.70 Million |
AU$-4.71 Million ≈ $-3.33 Million |
-0.900x | +51.72% |
| 2009-06-30 | AU$3.75 Million ≈ $2.65 Million |
AU$-6.99 Million ≈ $-4.95 Million |
-1.865x | -95.95% |
| 2008-06-30 | AU$9.89 Million ≈ $7.00 Million |
AU$-9.41 Million ≈ $-6.66 Million |
-0.952x | +41.93% |
| 2007-06-30 | AU$5.61 Million ≈ $3.97 Million |
AU$-9.20 Million ≈ $-6.51 Million |
-1.639x | -22.82% |
| 2006-06-30 | AU$8.73 Million ≈ $6.18 Million |
AU$-11.66 Million ≈ $-8.25 Million |
-1.335x | -129.03% |
| 2005-06-30 | AU$19.51 Million ≈ $13.81 Million |
AU$-11.37 Million ≈ $-8.05 Million |
-0.583x | -321.78% |
| 2004-06-30 | AU$38.47 Million ≈ $27.22 Million |
AU$-5.31 Million ≈ $-3.76 Million |
-0.138x | +39.11% |
| 2003-06-30 | AU$15.78 Million ≈ $11.16 Million |
AU$-3.58 Million ≈ $-2.53 Million |
-0.227x | -0.44% |
| 2002-06-30 | AU$16.68 Million ≈ $11.80 Million |
AU$-3.77 Million ≈ $-2.67 Million |
-0.226x | -- |
About Alterity Therapeutics Ltd
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II… Read more